What is 64Cu-PD-29875, which Peptidream is developing?

It is a cancer radiopharmaceutical candidate targeting Claudin18.2, expected for application in the diagnosis and treatment of gastric cancer and other cancers.

When did this clinical study begin?

According to the press release, the first administration to a subject has been announced. While a specific start date isn't mentioned, it was selected for an AMED research project in 2024.

What types of cancer are related to Claudin18.2?

It has been reported to be highly expressed in gastric cancer, esophageal cancer, pancreatic cancer, and lung adenocarcinoma, making it a promising target molecule.

What is radiotheranostics?

It is a medical approach that integrates diagnosis and treatment by using different isotopes for diagnostic and therapeutic purposes.

What is the current situation regarding gastric cancer?

Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death globally, known for its poor prognosis. The number of patients is on the rise.

AI News NQ Analysis

Peptidream Announces First Administration in a Specific Clinical Study of Cancer Radiopharmaceutical Candidate 64Cu-PD-29875 Targeting Claudin18.2 in Gastric Cancer Patients

Key facts

Peptidream Announces First Administration in a Specific Clinical Study of Cancer Radiopharmaceutical Candidate 64Cu-PD-29875 Targeting Claudin18.2 in Gastric Cancer Patients
Peptidream Inc. has administered the first dose to a subject in a specific clinical study of its cancer radiopharmaceutical candidate, 64Cu-PD-29875, which targets Claudin18.2. This first-in-human study aims to evaluate the safety, pharmacokinetics, and tumor uptake of 64Cu-PD-29875 in patients with gastric or gastroesophageal junction cancer using PET/CT imaging, exploring its potential as a diagnostic agent and for development into a therapeutic radiopharmaceutical.
Source: PR TIMES
Date: Fri Jun 12 2026 01:14:13 GMT+0900 (Japan Standard Time)

Direct answer

Peptidream Inc. has administered the first dose to a subject in a specific clinical study of its cancer radiopharmaceutical candidate, 64Cu-PD-29875, which targets Claudin18.2. This first-in-human study aims to evaluate the safety, pharmacokinetics, and tumor uptake of 64Cu-PD-29875 in patients with gastric or gastroesophageal junction cancer using PET/CT imaging, exploring its potential as a diagnostic agent and for development into a therapeutic radiopharmaceutical.

Citation: Peptidream Announces First Administration in a Specific Clinical Study of Cancer Radiopharmaceutical Candidate 64Cu-PD-29875 Targeting Claudin18.2 in Gastric Cancer Patients (Fri Jun 12 2026 01:14:13 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Fri Jun 12 2026 01:14:13 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Peptidream Inc. has administered the first dose to a subject in a specific clinical study of its cancer radiopharmaceutical candidate, 64Cu-PD-29875, which targets Claudin18.2. This first-in-human study aims to evaluate the safety, pharmacokinetics, and tumor uptake of 64Cu-PD-29875 in patients with gastric or gastroesophageal junction cancer using PET/CT imaging, exploring its potential as a diagnostic agent and for development into a therapeutic radiopharmaceutical.

AI Analysis

Frequently Asked Questions

Q: What is 64Cu-PD-29875, which Peptidream is developing?: A: It is a cancer radiopharmaceutical candidate targeting Claudin18.2, expected for application in the diagnosis and treatment of gastric cancer and other cancers.
Q: When did this clinical study begin?: A: According to the press release, the first administration to a subject has been announced. While a specific start date isn't mentioned, it was selected for an AMED research project in 2024.
Q: What types of cancer are related to Claudin18.2?: A: It has been reported to be highly expressed in gastric cancer, esophageal cancer, pancreatic cancer, and lung adenocarcinoma, making it a promising target molecule.
Q: What is radiotheranostics?: A: It is a medical approach that integrates diagnosis and treatment by using different isotopes for diagnostic and therapeutic purposes.
Q: What is the current situation regarding gastric cancer?: A: Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death globally, known for its poor prognosis. The number of patients is on the rise.